HAE - Haemonetics Corporation

https://www.haemonetics.com

Hold Momentum: Bearish

Recent News

These Analysts Slash Their Forecasts On Haemonetics After Q1 Results - Haemonetics ( NYSE:HAE )

Benzinga • 1 month, 1 week ago • score: 0.32

Haemonetics Corp HAE reported upbeat earnings for the first quarter on Thursday. The company posted quarterly earnings of $1.10 per share which beat the analyst consensus estimate of $1.02 per share. The company reported quarterly sales of $321.394 million which beat the analyst consensus ...

Neutral

This Trade Desk Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - Crocs ( NASDAQ:CROX ) , Haemonetics ( NYSE:HAE )

Benzinga • 1 month, 1 week ago • score: 0.02

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Neutral

Haemonetics ( HAE ) Q1 Earnings and Revenues Surpass Estimates

Zacks Commentary • 1 month, 1 week ago • score: 0.14

Haemonetics (HAE) delivered earnings and revenue surprises of +8.91% and +5.97%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Bullish

Haemonetics ( HAE ) Q1 Revenue Falls 4%

Motley Fool • 1 month, 1 week ago • score: 0.28

Haemonetics ( NYSE:HAE ) , a medical technology company specializing in blood and plasma collection and hospital technologies, reported its financial results for the first quarter of fiscal 2026 on August 7, 2025. The main headlines from the release included GAAP revenue of $321.4 million for Q1 ...

Neutral

Unlocking Q1 Potential of Haemonetics ( HAE ) : Exploring Wall Street Estimates for Key Metrics

Zacks Commentary • 1 month, 1 week ago • score: 0.07

Beyond analysts' top-and-bottom-line estimates for Haemonetics (HAE), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2025.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

As of 2025-09-10 (Snapshot)

Haemonetics Corporation, a healthcare company, offers medical products and solutions. The company is headquartered in Boston, Massachusetts.

52W High

$94.98

52W Low

$50.68

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.39

Valuation

Attractive

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

16.63

Forward P/E (<15 better)

11.16

EV/EBITDA (<8 favorable)

10.11

EV/Revenue (<3 favorable)

2.64

P/S (TTM) (<3 favorable)

1.95

P/B (<3 favorable)

2.97

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

1.15%

Institutions (25–75% balanced)

115.73%

Shares Outstanding

48,177,300

Float

47,598,200

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

1,346,046,000

Gross Profit (TTM)

791,115,000

EPS (TTM)

3.27

Profit Margin (>10% good)

0.12%

Operating Margin (TTM) (higher better)

0.20%

ROE (TTM) (>15% strong)

0.18%

EPS YoY (Quarterly) (>10% good)

-0.05

Revenue YoY (Quarterly) (>8% good)

-0.04

Momentum

Bearish momentum

Value

-2.9439

-2.9547

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025